This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Sep 6;367(10):945-6.

doi: 10.1056/NEJMe1206814.

Androgen deprivation--continuous, intermittent, or none at all?

PMID: 22931264
DOI: 10.1056/NEJMe1206814

Editorial

Androgen deprivation--continuous, intermittent, or none at all?

Oliver Sartor. N Engl J Med. 2012.

. 2012 Sep 6;367(10):945-6.

doi: 10.1056/NEJMe1206814.

Author

PMID: 22931264
DOI: 10.1056/NEJMe1206814

No abstract available

PubMed Disclaimer

Comment on

Intermittent androgen suppression for rising PSA level after radiotherapy.
Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Crook JM, et al. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. N Engl J Med. 2012. PMID: 22931259 Free PMC article. Clinical Trial.

Similar articles

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group. Salonen AJ, et al. J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11. J Urol. 2012. PMID: 22498230 Clinical Trial.
Intermittent androgen deprivation therapy with antagonist: really new information?
Mottet N. Mottet N. Eur Urol. 2014 Oct;66(4):664-5. doi: 10.1016/j.eururo.2014.06.044. Epub 2014 Jul 9. Eur Urol. 2014. PMID: 25023207 No abstract available.
The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. Boccon-Gibod L, et al. BJU Int. 2007 Oct;100(4):738-43. doi: 10.1111/j.1464-410X.2007.07053.x. Epub 2007 Jul 23. BJU Int. 2007. PMID: 17662079 Review. No abstract available.
Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
Walsh PC. Walsh PC. J Urol. 1998 Jul;160(1):270-1. doi: 10.1016/s0022-5347(01)63114-8. J Urol. 1998. PMID: 9628662 No abstract available.
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F. Sciarra A, et al. Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Eur Urol. 2013. PMID: 23628492 Review.

See all similar articles

Cited by

The RARγ Oncogene: An Achilles Heel for Some Cancers.
Brown G, Petrie K. Brown G, et al. Int J Mol Sci. 2021 Mar 31;22(7):3632. doi: 10.3390/ijms22073632. Int J Mol Sci. 2021. PMID: 33807298 Free PMC article. Review.
Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer.
Petrie K, Urban-Wójciuk Z, Sbirkov Y, Graham A, Hamann A, Brown G. Petrie K, et al. Cancer Rep (Hoboken). 2020 Dec;3(6):e1284. doi: 10.1002/cnr2.1284. Epub 2020 Sep 3. Cancer Rep (Hoboken). 2020. PMID: 32881426 Free PMC article.
Current clinical challenges in prostate cancer.
Silberstein JL, Pal SK, Lewis B, Sartor O. Silberstein JL, et al. Transl Androl Urol. 2013 Sep;2(3):122-36. doi: 10.3978/j.issn.2223-4683.2013.09.03. Transl Androl Urol. 2013. PMID: 26816735 Free PMC article. Review.
Trial Watch: DNA vaccines for cancer therapy.
Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Oncoimmunology. 2014 Jan 1;3(1):e28185. doi: 10.4161/onci.28185. Epub 2014 Apr 1. Oncoimmunology. 2014. PMID: 24800178 Free PMC article. Review.
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
Rick FG, Block NL, Schally AV. Rick FG, et al. Onco Targets Ther. 2013 Apr 16;6:391-402. doi: 10.2147/OTT.S32426. Print 2013. Onco Targets Ther. 2013. PMID: 23620672 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information